ArticleDiabetes, obesity & metabolism2026

Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.

Kathrine Kold Sørensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.